Assessing the Role of Bhallataka Ghrita Alongside Radiotherapy in Breast Cancer Treatment

A controlled comparative in-vitro and clinical study to assess the efficacy of bhallataka ghrita along with radiotherapy in the management of breast carcinoma - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/102409

Enrollment

Registered

2026-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Histopathologically confirmed cases of carcinoma of the breast Stage 1st to 3rd Age:30yrs-60yrs Sex: female No history of any other carcinoma in the past Has undergone modified radical mastectomy/Breast conversational surgery Planned for radiotherapy

Exclusion criteria

Exclusion criteria: Patients suffering from systemic disorders (like Diabetes Mellitus, Cardiac diseases, Pulmonary Tuberculosis, Essential Hypertension, SLE, Infectious Arthritis, Hypertrophic Arthropathy) Pregnant & Lactating women

Design outcomes

Primary

Measure	Time frame
1. In-Vitro Evaluation of the cytotoxic effect of Bhallataka extract on malignant breast cancer cell lines 2. Clinical outcome- assessment of the efficacy of Bhallataka ghrita as an adjuvant to radiotherapy in the patients with Breast cancer 3. Secondary outcome Evaluation of quality life improvements in patients using integrative treatment. Timepoint: 9 Weeks	—

Secondary

Measure	Time frame
Secondary outcome Evaluation of quality life improvements in patients using integrative treatment. Timepoint: 9 weeks	—

Countries

India

Contacts

Public ContactProf O P SINGH

faculty of ayurveda ims bhu

singhopbhu@gmail.com9415818732

Outcome results